Valuation: Laboratorios Richmond S.A.C.I.F.

Market Cap 125B 84.24M 73.1M 68.09M 62.58M 118M 8.04B 120M 802M 315M 4B 317M 310M 13.27B P/E 2024
6.08x
P/E 2025 51.6x
Enterprise Value 356B 240M 208M 194M 178M 336M 22.88B 342M 2.28B 897M 11.39B 901M 881M 37.75B EV / Sales 2024
3.04x
EV / Sales 2025 3.08x
Free-Float
17.54%
Yield 2024
1.5%
Yield 2025 -
05-11 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2026 CI
05-08 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
03-07 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
11-06 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
08/08/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
09/05/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2025 CI
08/05/25 Laboratorios Richmond S.A.C.I.F. announces Annual dividend, payable on May 15, 2025 CI
08/03/25 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2024 CI
06/11/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 CI
13/08/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2024 CI
07/05/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
11/03/24 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
10/11/23 Laboratorios Richmond S.A.C.I.F. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
1 day+0.32%
1 week+0.65%
1 month-1.27%
3 months-5.20%
6 months-22.11%
Current year-21.52%
1 week 1,520
Extreme 1520
1,595
1 month 1,495
Extreme 1495
1,610
Current year 1,420
Extreme 1420
2,130
1 year 945
Extreme 945
2,300
3 years 480.5
Extreme 480.5
2,300
5 years 215
Extreme 215
2,300
10 years 24.8
Extreme 24.8
2,300
Manager TitleAgeSince
President - -
General Counsel - 29/04/2025
Corporate Officer/Principal - 29/04/2025
Director TitleAgeSince
Director/Board Member - -
Director/Board Member - -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
+0.32%+0.65%+3.68%+190.26% 84.03M
-0.53%-3.95%+55.23%+152.74% 1,024B
+0.21%-2.68%+55.61%+53.02% 618B
-2.51%-3.25%+32.76%+67.76% 443B
+0.06%-0.42%+37.53%+30.67% 349B
-0.14%-0.24%+34.41%+39.01% 297B
-0.69%-0.30%+11.55%+12.93% 264B
-7.37%-4.40%-2.54%-43.87% 209B
-0.64%+2.43%+30.52%+64.49% 208B
-0.82%+0.70%+15.96%+71.01% 162B
Average -1.21%-0.95%+27.47%+63.80% 357.38B
Weighted average by Cap. -0.99%-1.93%+39.24%+72.96%

Financials

2024 2025
Net sales 91.79B 61.78M 53.61M 49.94M 45.9M 86.65M 5.9B 88.03M 588M 231M 2.94B 232M 227M 9.73B 127B 85.29M 74.01M 68.94M 63.36M 120M 8.14B 122M 812M 319M 4.05B 320M 313M 13.43B
Net income 23.85B 16.05M 13.93M 12.97M 11.92M 22.51M 1.53B 22.87M 153M 60.02M 763M 60.3M 58.97M 2.53B 3.09B 2.08M 1.8M 1.68M 1.54M 2.91M 198M 2.96M 19.79M 7.77M 98.78M 7.81M 7.64M 327M
Net Debt 134B 89.94M 78.05M 72.7M 66.82M 126M 8.58B 128M 856M 336M 4.28B 338M 331M 14.17B 231B 155M 135M 126M 116M 218M 14.84B 222M 1.48B 582M 7.39B 584M 571M 24.49B
Logo Laboratorios Richmond S.A.C.I.F.
Laboratorios Richmond SACIF is an Argentina-based company, which is engaged in the development and manufacture of pharmaceuticals. The Company's product categories include: Antiviral, under the brands Ciganclor, Lazinevir, Leuzan, Mivuten, Probirase, Protease, Selmivir, Trivenz, Virontar, Virontar N, Virontar 600, Vuclodir, Zepril, Zetavudin, and Zetrotax; Oncologi and Oncohematologic, under the brands Bemux, Capecit, Doxetal, Drifen, Espasevit, Fontrax, Gezt, and Monofer, among others; Cardiovascular, under the brands Amze 5, Amze 10, Antiplaq, Bilip 10, Bilip 20, Tacardia, and Timezol 20, among others; Neuropsychiatric, under the brands Dalam 15, Dolofrix 10, Donepes 5, and Prilben 10, among others, as well as Hospital, under the brands Amidiaz, Dalam, and Fentax, among others.
Employees
620
Date Price Change Volume
31/07/26 ARS 1,550.00 +0.32% 26,344
30/07/26 ARS 1,545.00 +0.32% 27,313
29/07/26 ARS 1,540.00 -.--% 31,156
28/07/26 ARS 1,540.00 +0.65% 400
27/07/26 ARS 1,530.00 -0.65% 34,559
  1. Stock Market
  2. Stocks
  3. RICH Stock